BCM
TAK icon

Bluefin Capital Management’s Takeda Pharmaceutical TAK Stock Holding History

Bluefin Capital Management’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-688,000
Closed -$230K – 467
2019
Q1 		$230K Buy
688,000
+678,000
+6,780% +$13.6M 0.03% 203
2018
Q4 		$13K Buy
+10,000
New +$169K ﹤0.01% 373

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bluefin Capital Management's TAK Position: Q1 2026 in Review

Bluefin Capital Management opened a new position in Takeda Pharmaceutical (TAK) in Q1 2026: 10,900 shares worth $202K. The stake represents 0.13% of the portfolio and ranks #74 among its holdings. This is a return to the name: Bluefin Capital Management previously reported a position in TAK as recently as Q3 2021.

Bluefin Capital Management first reported a position in TAK in Q1 2019 and has held it in 4 quarters since. The position peaked at $24.5M in Q1 2019. 359 funds tracked by Wall St. Rank hold TAK as of Q1 2026.

  • Bluefin Capital Management held 10,900 shares of Takeda Pharmaceutical worth $202K as of Q1 2026.
  • Takeda Pharmaceutical was a new Bluefin Capital Management position in Q1 2026.
  • Takeda Pharmaceutical made up 0.13% of Bluefin Capital Management's portfolio in Q1 2026, its #74 holding.
  • Bluefin Capital Management first reported a position in Takeda Pharmaceutical in Q1 2019 and has held it in 4 quarters since.
  • Bluefin Capital Management's Takeda Pharmaceutical position peaked at $24.5M in Q1 2019.
  • 359 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2026.

Based on Bluefin Capital Management's 13F filing for Q1 2026, filed 15 May 2026.